Announcements
13 January 2025
Cancers | Highly Viewed Papers in 2024 and Hot Topic Special Issues on Cancer Pathophysiology
We are delighted to share some highly viewed papers on cancer pathophysiology that were published in the journal Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“Molecular Characterization and Xenotransplantation of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA)”
by Lilia Antonova, Piriya Paramanthan, Theresa Falls, Marie-Eve Wedge, Justin Mayer, Harman S. Sekhon, John McPherson, Robert E. Denroche, Steven Gallinger, John Cameron Bell et al.
Cancers 2024, 16(15), 2721; https://doi.org/10.3390/cancers16152721
Available online: https://www.mdpi.com/2072-6694/16/15/2721
“Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma”
by Centura R. Anbarasu, Sophia Williams-Perez, Ernest R. Camp and Derek J. Erstad
Cancers 2024, 16(16), 2773; https://doi.org/10.3390/cancers16162773
Available online: https://www.mdpi.com/2072-6694/16/16/2773
“Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS/MS Analysis and Immunohistochemical Validation”
by Michał Kasperczak, Gabriel Bromiński, Iga Kołodziejczak-Guglas, Andrzej Antczak and Maciej Wiznerowicz
Cancers 2024, 16(16), 2844; https://doi.org/10.3390/cancers16162844
Available online: https://www.mdpi.com/2072-6694/16/16/2844
“Impact of Breast Cancer on Cardiometabolic Health in Spanish Women ≥50 Years with Pre-Existing Type 2 Diabetes Mellitus”
by Lucía Fernández-Arce, Nena Robles-Rodríguez, Ana Fernández-Feito, Rocío Fernández-Iglesias, María del Mar Fernández-Álvarez and Alberto Lana
Cancers 2024, 16(16), 2853; https://doi.org/10.3390/cancers16162853
Available online: https://www.mdpi.com/2072-6694/16/16/2853
“Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor”
by Kia Teng Lim and Amos H. P. Loh
Cancers 2024, 16(17), 3051; https://doi.org/10.3390/cancers16173051
Available online: https://www.mdpi.com/2072-6694/16/17/3051
“Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer”
by Noémie Thomas, Soizic Garaud, Mireille Langouo, Doïna Sofronii, Anaïs Boisson, Alexandre De Wind, Valérie Duwel, Ligia Craciun, Dennis Larsimont, Ahmad Awada et al.
Cancers 2024, 16(16), 2895; https://doi.org/10.3390/cancers16162895
Available online: https://www.mdpi.com/2072-6694/16/16/2895
|
|
|
|
“Histopathology of Urological Cancers” |
“The Pathology of Biliary Tract Carcinoma (BTC)” |
|
|
|
|
“Pathology and Treatment of Triple-Negative Breast Cancer” |
“Clinical Pathology of Lung Cancer” |
We hope this announcement will provide useful information for the field of cancer pathophysiology.
Cancers Editorial Office
13 January 2025
Cancers | Highly Viewed Papers in 2024 and Hot Topic Special Issues on Clinical Research of Cancer
We are delighted to share some highly viewed papers on clinical research of cancer that were published in the journal Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma”
by Sami Fares, Chase J. Wehrle, Hanna Hong, Keyue Sun, Chunbao Jiao, Mingyi Zhang, Abby Gross, Erlind Allkushi, Melis Uysal, Suneel Kamath et al.
Cancers 2024, 16(8), 1453; https://doi.org/10.3390/cancers16081453
Available online: https://www.mdpi.com/2072-6694/16/8/1453
“Atypical Endometrial Hyperplasia and Concurrent Cancer: A Comprehensive Overview on a Challenging Clinical Condition”
by Luca Giannella, Camilla Grelloni, Marco Bernardi, Camilla Cicoli, Federica Lavezzo, Gianmarco Sartini, Leonardo Natalini, Mila Bordini, Martina Petrini, Jessica Petrucci et al.
Cancers 2024, 16(5), 914; https://doi.org/10.3390/cancers16050914
Available online: https://www.mdpi.com/2072-6694/16/5/914
“Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts”
by Jacqueline Schönherr, Philipp Seifert, Falk Gühne, Thomas Winkens, Falk Rauchfuß, Utz Settmacher, Martin Freesmeyer and Robert Drescher
Cancers 2024, 16(1), 235; https://doi.org/10.3390/cancers16010235
Available online: https://www.mdpi.com/2072-6694/16/1/235
“Venetoclax Resistance in Acute Myeloid Leukemia”
by Sylvain Garciaz, Marie-Anne Hospital, Yves Collette and Norbert Vey
Cancers 2024, 16(6), 1091; https://doi.org/10.3390/cancers16061091
Available online: https://www.mdpi.com/2072-6694/16/6/1091
“Emerging Therapies for Glioblastoma”
by Stella Aimé Rios, Stephanie Oyervides, David Uribe, Angelica Maree Reyes, Victor Fanniel, Jonathan Vazquez and Megan Keniry
Cancers 2024, 16(8), 1485; https://doi.org/10.3390/cancers16081485
Available online: https://www.mdpi.com/2072-6694/16/8/1485
“Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma”
by Omar Nadeem, Sikander Ailawadhi, Jack Khouri, Louis Williams, Donna Catamero, Kathryn Maples and Jesús Berdeja
Cancers 2024, 16(5), 1023; https://doi.org/10.3390/cancers16051023
Available online: https://www.mdpi.com/2072-6694/16/5/1023
|
“Melanoma: Clinical Trials and Translational Research” |
“Acute Myeloid Leukemia in Adults” |
|
“Current Progress in the Clinical Management and Basic Science of Head and Neck Cancer” |
“Clinical Outcomes in Urologic Cancers” |
We hope this announcement will provide useful information for the field of clinical research of cancer.
Cancers Editorial Office
13 January 2025
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Causes, Screening and Diagnosis
We are delighted to share some highly viewed papers on cancer causes, screening and diagnosis that were published in Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you. The list of relevant papers can be seen below.
“Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma”
by K. Wunderlich, M. Suppa, S. Gandini, J. Lipski, J. M. White and V. Del Marmol
Cancers 2024, 16(5), 1016; https://doi.org/10.3390/cancers16051016
Available online: https://www.mdpi.com/2072-6694/16/5/1016
“PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer”
by Nicholas Hirschl, Wildnese Leveque, Julia Granitto, Valia Sammarco, Mervyns Fontillas and Richard T. Penson
Cancers 2024, 16(5), 932; https://doi.org/10.3390/cancers16050932
Available online: https://www.mdpi.com/2072-6694/16/5/932
“Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets”
by Sofianidi Amalia, Ecaterina E. Dumbrava, Konstantinos N. Syrigos and Azadeh Nasrazadani
Cancers 2024, 16(6), 1139; https://doi.org/10.3390/cancers16061139
Available online: https://www.mdpi.com/2072-6694/16/6/1139
“Artificial Intelligence in Urologic Robotic Oncologic Surgery: A Narrative Review”
by Bellos Themistoklis, Ioannis Manolitsis, Stamatios Katsimperis, Patrick Juliebø-Jones, Georgios Feretzakis, Iraklis Mitsogiannis, Ioannis Varkarakis, Bhaskar K. Somani and Lazaros Tzelves
Cancers 2024, 16(9), 1775; https://doi.org/10.3390/cancers16091775
Available online: https://www.mdpi.com/2072-6694/16/9/1775
“Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)”
by Restaino Stefano, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Alfredo Ercoli, Francesco Fanfani et al.
Cancers 2024, 16(14), 2541; https://doi.org/10.3390/cancers16142541
Available online: https://www.mdpi.com/2072-6694/16/14/2541
“The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)”
by Fischerova Daniela, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti and David Cibula
Cancers 2024, 16(4), 775; https://doi.org/10.3390/cancers16040775
Available online: https://www.mdpi.com/2072-6694/16/4/775
Special Issues:
“Clinical Diagnosis, Treatment, and Prognosis of Uveal Melanoma”
Guest Editor: Dr. Josep Maria Caminal Mitjana
Submission deadline: 30 June 2025
“Screening, Diagnosis and Staging of Lung Cancer”
Guest Editors: Dr. Ioannis Gkiozos and Dr. Andriani G. Charpidou
Submission deadline: 10 June 2025
“Breast Cancer Imaging: Current Trends and Future Direction (2nd Edition)”
Guest Editor: Prof. Dr. Angela Spanu
Submission deadline: 30 April 2025
“Women’s Health and Gynaecological Cancers: From Nutrition and Environmental Factors to Novel Diagnostics and Therapies”
Guest Editors: Prof. Dr. Emmanouil Karteris, Dr. Ioannis Kyrou, Prof. Dr. Harpal S. Randeva and Prof. Dr. Harpal S. Randeva
Submission deadline: 31 March 2025
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
10 January 2025
Cancers | Cervical Cancer Awareness Month
10 January 2025
Recruiting Early Career Editorial Board Members for Cancers
7 January 2025
MDPI INSIGHTS: The CEO's Letter #19 - Reflecting on 2024, Society Journals, OA Germany
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Reflecting on 2024: Celebrating Our Progress and People
As we reflect on the year gone by, I’m proud and thankful for what we’ve accomplished together. This has been a year of growth, learning, and resilience, all of which have shaped MDPI’s journey. I would like to thank each of our employees for their dedication, hard work, and commitment to advancing open access (OA) publishing.
Our growth is evident: from about 5,900 colleagues at the end of 2023 to over 6,650 today, our global MDPI community continues to expand. We expanded our global operations with a new office in Seoul, South Korea, and celebrated a record-breaking year with 60 MDPI journals newly indexed in the Web of Science and 37 MDPI journals accepted into Scopus. As at 30 December, 2024, we publish 457 journals, of which 448 are peer-reviewed and 9 dedicated to academic conference outputs. Of these, 306 are indexed in Scopus, 298 in the Web of Science, and 90 in PubMed.
Looking for a new role in 2025? We have a variety of roles currently open!
Yet, growth never comes without its challenges. This year, we faced setbacks, including the removal of the Journal of Personalized Medicine from the Web of Science due to content relevance concerns. Our editorial and research integrity teams are actively addressing these issues, and we aim to reapply for indexation in December 2026. On another front, the decision by JUFO, The Finnish Publication Forum, to downgrade many MDPI journals presented a challenge. However, we are engaging with the Finnish research community and our editorial boards to provide scientific data supporting a reevaluation of MDPI journals in alignment with Finland’s national open access policies.
These examples remind us that challenges are part of our journey. What defines us is how we respond, by learning, adapting, and improving our practices and operations.
On the partnerships front, we achieved a landmark national open access agreement with over 100 German universities, effective 1 January 2025, bringing our total of Institutional Open Access Program (IOAP) partners to over 950. These achievements reflect not just our ambition but also the trust placed in MDPI by our collaborators worldwide.
Amidst growth and change, one constant remains: the people of MDPI. This year, I had the privilege of representing MDPI at important meetings and conferences from Beijing to Krakow, while visiting many of our offices, from Tokyo and Cluj to Manchester and Toronto. The highlight of my year has been meeting and connecting with so many of you.
“MDPI thrives because of community and collaboration”
When asked what makes MDPI a great place to work, my answer is simple: It’s the people. Our authors frequently praise the support and professionalism of our editorial staff. That same care extends inward, reflected in the friendships and collaborations we regularly nurture with our colleagues. MDPI thrives because of the community and collaboration that drives us forward.
As the African proverb states, “If you want to go fast, go alone. If you want to go far, go together.” I believe MDPI embodies both, being speedy in our daily operations and united in our purpose of promoting open access publishing.
Looking ahead to 2025, let us continue building a culture of care and support for one another, take pride in our work, and strive to improve all that we do. Thank you for making 2024 a special year, and I look forward to what we can achieve together in 2025.
PS: I look forward to sharing more about our people and the achievements of the past year in the 2024 Annual Report.
Impactful Research
685 MDPI Editors Named Highly Cited Researchers in 2024
I’m excited to celebrate the achievements of 685 Editorial Board Members (EBMs) from our journals, representing 39 countries and territories, who have been named Highly Cited Researchers for 2024 by Clarivate. This prestigious recognition highlights their scientific contributions, which transcend academic boundaries to drive progress in global knowledge, sustainability, security, and well-being.
Here, you’ll find the list of MDPI’s EBMs who have been recognized this year.
Clarivate’s annual Highly Cited Researcher™ list identifies the most influential scientists of the past decade – those whose work has made a profound and far-reaching impact across numerous scientific and social science disciplines. To be included on this list is no small feat. These researchers’ impactful papers rank among the top 1% by citations in one or more of the 21 fields analyzed within the “Essential Science Indicators,” positioning them as leaders in their domains.
As Clarivate notes, “Highly Cited Researchers have demonstrated significant and broad influence in their field(s) of research.” In 2024, a total of 6,886 Highly Cited Researcher designations were awarded to 6,636 individuals globally.
I extend my congratulations to all of MDPI’s EBMs who have achieved this milestone. Their dedication and excellence inspire us all and exemplify the high standards we uphold as a publisher. Congratulations to each of them for this incredible accomplishment and for their ongoing contributions to advancing knowledge in their fields.
Inside MDPI
How MDPI / Open Access Supports Societies
MDPI actively supports societies through the launch of new journals, the acquisition of established journals, and the transfer of society journals from other publishers. You can submit your proposal here.
Over the past 13 years, we have collaborated with over 190 learned societies and organizations. These partnerships range from affiliations with one or more of our journals to publishing journals on behalf of our partners.
Learn about how MDPI / Open Access Supports Societies.
In this section I highlight our Societies team, whose responsibilities include establishing new OA journals on behalf of societies and institutions, publishing an existing OA journal with MDPI or transitioning a subscription journal to an OA model, and establishing affiliations between societies and MDPI journals.
If you would like to learn more about these services, please see the Societies website.
The Societies team is led by Dr. Carla Aloè, Head of Societies and Acquisition, and her Deputy Manager, Dr. Clàudia Aunós. MDPI collaborates with a wide range of societies through various partnerships. For a complete list of collaborating societies and society journals, please visit the Societies website.
How long have you been at MDPI, and what was your first role?
I joined MDPI in September 2020 as an Associate Publisher and Scientific Officer, overseeing the Arts, Humanities, and Social Science journals. In July 2022, I took on the oversight of the Society and Acquisition team.
Do you think that perceptions of Open Access are generally accurate?
Far from it: there are in fact many misconceptions surrounding the way Open Access works and the benefits it has to offer. A common misconception is that OA journals are poor quality, which is entirely untrue. Many of our journals are included in major indexing databases, and all of them are endorsed by prominent associations and committees such as the Committee on Publication Ethics (COPE), the International Association of Scientific, Technical, and Medical Publishers (STM), and the Open Access Scholarly Publication Association (OASPA). We uphold a rigorous peer-review process, adhere to strict ethical standards, and rely on high-profile editorial boards.
How long have you been at MDPI, and what was your first role?
I’ve been at MDPI for almost seven years now. I started as an Assistant Editor but was quickly promoted to work with societies.
What is the most common question you get asked about the services that the Societies team provides?
For societies with a standard number of members (less than 500), the most common inquiry is about how much the publishing services we offer cost. One of the great things about our publishing services is that they are free of any burden cost to the society, regardless of the type of non-profit organization.
For bigger non-profit organizations, it is more about what benefits they can get for their members and ensuring that their journals are in good hands.
Either way, the goal is the same: to listen to the demands of the market, be flexible, and help our partners achieve healthy and positive development of their journals.
Read more:
Coming Together for Science
2024 MDPI Conference Summary
Throughout 2024, the MDPI Conference Team connected with scientific communities by organizing nine in-person events and 26 virtual conferences. In order to support the need for our growing events, we expanded this team to a total of 37 people across all offices, including 18 members in Asia-Pacific and 20 in the EU and North America.
The nine large-scale in-person conferences organized brought together leading minds across diverse disciplines, including our conferences on Viruses, Molecules, Polymers, Materials, Non-Coding RNA, Pharmaceuticals, and Sensors. These events strengthened synergies with the scientific community, actively promoting our journals and the latest research published within their respective fields. These achievements highlight our Conference Team’s dedication to creating meaningful and memorable events in the academic field.
2024 Event Highlights
Viruses 2024, the 5th edition of the conference series, hosted influential keynote speeches from Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes. The event attracted 240 attendees from around the globe. With 47 talks and nearly 130 poster presentations, the conference explored the latest developments in viral pathogenesis and immune responses across six engaging sessions.
Molecules 2024, the fourth edition of this conference series, highlighted the impact of emerging drug modalities on drug discovery. The event brought together over 100 attendees from 22 countries and featured more than 80 submissions organized into six sessions. The program included talks by 12 invited speakers from Europe, Asia and the United States. An impressive 97% of attendees rated the conference as ‘Excellent’ or ‘Good.’
Polymers 2024, attracted over 300 attendees from 22 countries and featured 259 accepted abstracts. Focusing on green polymer chemistry and the use of bioresources, the conference highlighted advancements in the synthesis of biobased and biodegradable polymers. Engaging lectures by three keynote speakers and 12 invited speakers, coupled with dynamic discussions, led 94% of attendees to rate the conference as ‘Excellent’ or ‘Good.’
A high-profile summit in Toronto was organized by the team, which expanded our global reach and showcased our capacity to deliver impactful events in our different offices. Sixteen EiC and seven EBMs joined our event, and with a 100% rate of Excellent/Good, over 90% of them said they are likely to attend our next edition.
The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science successfully gathered about 400 participants onsite. Three hundred and fifty-five abstracts were accepted, with 772 authors from 28 countries. Across the four-day program, there were 296 talks delivered and 66 posters displayed.
The 2nd Sustainable Publishing Forum was successfully held in Beijing, China, with around 120 attendees from local publishers, editorial staff from local university presses, librarians, etc. The event is focused on promoting open science, maintaining research integrity and fulfilling social responsibility.
ICM 2024, the 5th International Conference on Materials, brought together scientists, researchers and industry leaders to explore advancements in materials characterization, processing and manufacturing. Topics ranged from nanotechnology and biomaterials to energy materials and AI-driven research. With 62 attendees from 26 different countries, the program featured 34 talks and 18 posters, fostering collaboration and innovation over 2.5 days.
The second edition of ncRNA 2024 welcomed 104 attendees from 30 countries, 71% of them being women. Two keynote speakers, Prof. Ling-Ling Chen and Prof. Mauro Giacca, shared insights drawn from over 10 years of experience. Prof. Giacca's groundbreaking work promises advances in curative therapies for heart failure, while Prof. Chen’s team continues to lead the development of the ncRNA field. High participant engagement generated valuable topics for future editions, and 96% of attendees rated the conference as ‘Excellent’ or ‘Good’.
Pharmaceuticals 2024, with its eight sessions, covered the newest technologies and the research areas of medicinal chemistry, natural products, organic synthesis, radiopharmaceuticals, pharmacology, toxicology, and biomolecular and glycosciences, among others. The conference featured three plenary and eight invited speakers, comprising esteemed scholars from eight different countries of Europe, and welcomed 64 participants from 28 different countries. Ninety-one percent of the attendees rated the conference as ‘Excellent’ or ‘Good’, highlighting the outstanding organzation of the event.
In 2024, we organized 26 virtual events with an average submission number of 158 abstracts per event, and an average registration number of 491 per event. Compared with the last edition, we saw a 42.2% growth of accepted abstract submissions.
The year 2024 marked a change in the strategy of our conference team, prioritizing the improvement of the communication and collaboration within our European and Asia-Pacific teams and creating stronger teamwork to elevate the quality and impact of MDPI events.
Scheduled Events in 2025
- Smart Sustainable Cities 2025: Pioneering Novel Frontiers for Green Urban Living: 5–7 Mar 2025, online.
- International Conference on Advanced Remote Sensing (ICARS 2025): 26–28 Mar 2025, Barcelona, Spain.
- Plants 2025: From Seeds to Food Security: 31 Mar–2 Apr 2025, Barcelona, Spain.
- Symmetry 2025 - The 5th International Conference on Symmetry: 16–19 May 2025, Hangzhou, China.
- The 2nd International Conference on AI Sensors and Transducers: 29 Jul–3 Aug 2025, Bangkok, Thailand.
- The 5th International Symposium on Frontiers in Molecular Science: 26–29 Aug 2025, Kyoto, Japan.
- The 11th World Sustainability Forum: Sustainable and Resilient Cities: 2–3 Oct 2025, Barcelona, Spain.
- The Cancers 2025 and Sensors 2025 websites will soon be made public.
Closing Thoughts
Over 100 German Universities Partner with MDPI in New National Agreement
I am pleased to share some exciting end-of-year news: MDPI has reached a major milestone by signing a publishing agreement with over 100 German universities and research institutions! Negotiated by ZB MED - Informationszentrum Lebenswissenschaften, the agreement came into effect on 1 January 2025 and will run until the end of 2026.
This new cooperation aims to make scientific Gold Open Access publishing more affordable and less administratively burdensome for researchers in Germany.
Learn more, here.
“Thank you to everyone who contributed to making this agreement a reality.”
Why is this important?
Germany is a global leader in academic research and publishing, ranking fifth in total MDPI publication volume.
This agreement reflects our growing influence and leadership in open access publishing.
Partnering with more than 100 institutions highlights MDPI’s reputation as a trusted publishing partner for the academic community.
As Peter Roth, MDPI Head of Publishing, noted:
“MDPI can look back on over a decade of successful partnerships with German research institutions. This agreement marks another milestone in our collaboration with the German scientific community.”
Adrian Stefan Zamfir, Institutional Partnership Manager for the DACH region, added:
“We are delighted that this agreement will give even more researchers in Germany access to our tried-and-tested and reliable publication platform”
Thank you to everyone who contributed to making this agreement a reality. This milestone reinforces MDPI as a trusted leader in advancing open access and supporting researchers worldwide.
Chief Executive Officer
MDPI AG
20 December 2024
Welcoming New Editorial Board Members of Cancers
We are pleased to announce that five new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694) in 2024. We wish our new members success in both their research and the efforts to develop the journal.
Name: Dr. Leonhard Müllauer
Affiliation: Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
Interests: molecular pathology; apoptosis; targeted therapy
Name: Dr. Jason Li
Affiliation: Peter Maccallum Cancer Centre, Melbourne, Australia
Interests: bioinformatics; cancer; artificial intelligence; genomics; imaging; large language models; facility management
Name: Prof. Dr. Arun Dharmarajan
Affiliations: 1. School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA, Australia
2. School of Human Sciences, The University of Western Australia, Nedlands, Perth, WA 6009, Australia
Interests: Wnt signaling; secreted frizzled related protein 4; cancer; cancer stem cells; angiogenesis; apoptosis; redox signaling; molecular modeling
Name: Dr. Francesca Pentimalli
Affiliation: Department of Medicine and Surgery, LUM University Giuseppe DeGennaro, 70010 Casamassima, Italy
Interests: cell cycle; mesothelioma; DNA damage; tumor suppressor genes; RB family; p53; oncolytic viruses; cell death; CDK inhibitors; p27
Name: Prof. Dr. Yicheng Ni
Affiliation: Department of Radiology, Affiliated Zhongda Hospital, Southeast University, Nanjing, China
Interests: imaging-navigated translational theragnostic research
Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.
Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office (cancers@mdpi.com) and provide the following files:
- A full academic CV;
- A short cover letter that details your interest in the position.
17 December 2024
Cancers | Notable Papers in the Field of Cancer Cell Plasticity
17 December 2024
Over 100 German Universities Partner with MDPI in New National Agreement
More than 100 German universities and research institutions have entered into a national agreement with MDPI. The publication agreement negotiated by ZB MED comes into effect on 1 January 2025 and is valid until the end of 2026. Joining the consortium is still possible until the beginning of 2025. We are delighted by the high level of interest this agreement has already garnered, reflecting the strong demand for accessible and cost-effective open access publishing solutions among German research institutions.
This new cooperation aims to make scientific gold open access publishing more affordable and less administratively burdensome for researchers in Germany. The agreement includes substantial discounts on article processing charges (APCs) for corresponding authors from participating institutions. It offers flexible payment options, including centralized invoicing or individual payment of fees by researchers or their institutions. Additionally, the agreement features a flat-fee model that enables institutions to precisely plan expenses and optimize their library budgets.
"MDPI can look back on over a decade of successful partnerships with German research institutions," says Peter Roth, MDPI Head of Publishing. "The new agreement marks another milestone in the long-standing co-operation between MDPI and the German scientific community. It emphasizes our commitment to developing up-to-date and inventive solutions for the diverse needs of scientific institutions to promote open research for the benefit of researchers."
Petra Labriga, Head of Strategic License Management at ZB MED, highlighted the agreement's significance: "As one of the world's leading Gold OA publishers, MDPI plays a central role in the German publishing landscape. We are particularly pleased that we were able to achieve considerable potential cost savings for scientific institutions and their authors at a national level through our negotiations."
The partnership reflects a common goal of advancing the idea of open access and supporting researchers in making their scientific excellence internationally visible.
"We would like to thank the ZB MED consortium team for their excellent collaboration," added Adrian Stefan Zamfir, MDPI Institutional Partnership Manager for the DACH region. "We are delighted that this agreement will give even more researchers in Germany access to our tried-and-tested and reliable publication platform."
Franziska Fischer (right), Commercial Director at ZB MED, an Peter Roth (left), Head of Publishing at MDPI, celebrate the signing of the new national open access agreement between MDPI and the ZB MED Consortium.
More Information
Contact
- ZB MED: Team Konsortiallizenzen (konsortiallizenzen@zbmed.de) - Website
MDPI: Adrian Stefan Zamfir, Institutional Partnership Manager (zamfir@mdpi.com)
About ZB MED
ZB MED - Information Centre for Life Sciences is an infrastructure and research centre for life science information and data. Its aim is to support and strengthen research for people and the environment: from medicine to biodiversity and environmental protection.
The work of ZB MED is orientated towards the strategic guidelines:
- Research + Networking: We conduct research together with the regionally, nationally, European and globally networked research community.
- Data science: We enable data analyses and generate new knowledge through research.
- Access to information: We provide sustainable access to information, literature and data as a central information infrastructure.
- Open + FAIR: We promote open and reproducible science in line with open science and FAIR principles.
- Knowledge and skills transfer: We actively impart knowledge, competences and skills.
More information at www.zbmed.de.
About MDPI
Headquartered in Basel, Switzerland, MDPI is one of the world's leading open access publishers with a current portfolio of more than 440 journals in all scientific disciplines. MDPI‘s goal is to advance open science worldwide through greater transparency, efficiency and collaboration. To date, more than 3.7 million researchers have published their results in MDPI journals. The editorial process is overseen by a large network of dedicated reviewers and editors and supported by more than 6500 MDPI employees. MDPI currently works with over 800 academic institutions and 180 scientific societies worldwide, which benefit from a wide range of MDPI services and products.
17 December 2024
Meet Us at the AACR Annual Meeting 2025, 25–30 April 2025, Chicago, IL, USA
